Cibus - Class A (CBUS) closed at $1.13 on November 13, 2026, up 3.7% from the previous close, on volume of 147,579 shares (30-day average 94,068).
Data as of November 13, 2026.
H.C. Wainwright Sticks to Its Buy Rating for Cibus (CBUS)
TipRanks (Fri, 13-Nov 9:39 AM ET)
Cibus GAAP EPS of -$0.29 misses by $0.12, revenue of $0.80M misses by $0.48M
Seeking Alpha News (Thu, 12-Nov 4:43 PM ET)
Cibus Reports Third Quarter Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Cibus Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 5:35 PM ET)
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
Cibus and Crystal Crop Protection Team Up to Improve India's Mustard Crop
Globe Newswire (Mon, 28-Sep 4:05 PM ET)
Cibus Reports Second Quarter Financial Results and Provides Business Update
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Cibus - Class A trades on the NASDAQ stock market under the symbol CBUS.
As of November 13, 2026, CBUS stock price climbed to $1.13 with 147,579 million shares trading.
CBUS has a beta of 2.11, meaning it tends to be more sensitive to market movements. CBUS has a correlation of 0.07 to the broad based SPY ETF.
CBUS has a market cap of $86.36 million. This is considered a Micro Cap stock.
Last quarter Cibus - Class A reported $800,000 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-500,400 and missed earnings estimates by -$.10.
In the last 3 years, CBUS traded as high as $23.18 and as low as $1.02.
The top ETF exchange traded funds that CBUS belongs to (by Net Assets): VTI, VXF, IWC, KROP.
CBUS has underperformed the market in the last year with a price return of -16.3% while the SPY ETF gained +11.5%. CBUS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.2% and -16.3%, respectively, while the SPY returned -2.1% and -1.9%, respectively.
CBUS support price is $1.01 and resistance is $1.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBUS shares will trade within this expected range on the day.